Bernstein Harold 4

4 · Maze Therapeutics, Inc. · Filed Apr 2, 2026

AI-generated summary of this filing

Updated Apr 2, 2026

Maze Therapeutics (MAZE) CMO Harold Bernstein Exercises Options, Sells Shares

What Happened

Harold Bernstein, President, R&D & Chief Medical Officer of Maze Therapeutics, exercised 15,000 stock option shares (reported as an "M" transaction) at $10.42 per share (cost $156,300) on 2026-04-01 and sold a total of 15,000 shares that same day in three open‑market transactions for combined proceeds of $441,904.
The filing also reports a separate 15,000‑share derivative disposition at $0.00 (listed as a derivative disposal). The Form 4 does not provide further detail about that zero‑dollar line beyond the transaction code.

Key Details

Transaction date: 2026-04-01; Form 4 filed 2026-04-02 (timely filing).
Option exercise: 15,000 shares @ $10.42 (total $156,300).
Open‑market sales: 11,352 shares @ $29.24 (weighted avg; range $28.77–$29.75), 3,348 shares @ $30.06 (range $29.77–$30.50), and 300 shares @ $31.07 (range $30.80–$31.22) — total proceeds $441,904.
Additional line: 15,000 shares reported disposed as a derivative at $0.00 (no cash reported).
Shares owned after the transactions: not disclosed in the provided filing excerpt.
Footnotes: sales were effected under a Rule 10b5‑1 trading plan adopted Sept 29, 2025 (F1). Vesting schedule for the option award is noted (1/4 on Oct 3, 2023, then monthly 1/48th) (F5). Weighted‑average pricing details provided in F2–F4.

Context

This was an exercise followed by immediate open‑market sales (common practice to monetize vested option shares). The insider paid the exercise price ($156.3K) and realized gross sale proceeds of ~$442K the same day.
The zero‑dollar derivative disposition is shown on the form but not explained in the filing; Form 4s sometimes include such lines for net settlements or withholding, but the filing here does not specify the reason.

Form 4

Period: 2026-04-01

President, R&D & CMO

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-04-01$10.42/sh+15,000$156,300→ 15,000 total
Sale
Common Stock
[F1][F2]
2026-04-01$29.24/sh−11,352$331,948→ 3,648 total
Sale
Common Stock
[F1][F3]
2026-04-01$30.06/sh−3,348$100,636→ 300 total
Sale
Common Stock
[F1][F4]
2026-04-01$31.07/sh−300$9,320→ 0 total
Exercise/Conversion
Stock Option (Right to Buy)
[F1][F5]
2026-04-01−15,000→ 237,407 total
Exercise: $10.42Exp: 2032-10-26→ Common Stock (15,000 underlying)

Footnotes (5)

[F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
[F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.77 to $29.75 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4.
[F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.77 to $30.50 per share, inclusive.
[F4]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.80 to $31.22 per share, inclusive.
[F5]The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

Signature

/s/ Courtney Phillips, as attorney-in-fact|2026-04-02

1 file